Today: 8 June 2026
Woodside Energy share price jumps after Q4 report, but 2026 output dip keeps traders cautious
28 January 2026
1 min read

Woodside Energy share price jumps after Q4 report, but 2026 output dip keeps traders cautious

Sydney, January 28, 2026, 16:59 AEDT — Market closed

  • Shares of Woodside Energy climbed 2.7%, closing at A$24.98 following its fourth-quarter update.
  • The producer signaled a dip in 2026 output, gearing up for scheduled downtime at Pluto LNG while awaiting Scarborough volumes.
  • Investors are turning their attention to the Scarborough timing and Woodside’s annual report briefing set for Feb. 24.

Woodside Energy Group Ltd (ASX:WDS) shares climbed Wednesday following the release of its record production forecast for 2025 and updates on major growth projects, despite signaling a decline in this year’s output. The stock was last seen at A$24.98, up 2.7% from the previous close, based on data delayed by at least 20 minutes.

Woodside is entering a challenging period, with a packed project schedule set to cause disruptions through the year. The company projects 2026 output between 172 million and 186 million barrels of oil equivalent, as a significant turnaround at Pluto LNG coincides with a June-quarter slowdown and Scarborough gas production arriving later than anticipated by some investors. Nik Burns from Jarden suggested the market might “take it in its stride,” while Saul Kavonic at MST Marquee noted the results underscore a broader move toward more cautious guidance, according to Reuters. Reuters

Woodside reported December-quarter revenue dropped to $3.035 billion from $3.484 billion a year earlier, as its average realised price fell to $57 per barrel of oil equivalent (boe). Acting CEO Liz Westcott highlighted a record annual production of 198.8 million boe in 2025 and noted Scarborough is 94% complete, aiming for its first LNG cargo in Q4 2026. The company also confirmed first production at the Beaumont New Ammonia project in late December and said the 2025 annual report and results briefing are set for Feb. 24.

Traders see 2026 guidance as a bridge year. The figures reveal more about timing than actual demand — what production continues, what pauses, and when fresh barrels and LNG volumes come online.

The Scarborough schedule is crucial since it feeds directly into Woodside’s Australian LNG operations. Any delay would stretch the “gap” during Pluto’s downtime from a brief quarter to a prolonged issue.

The broader market gave little boost. Australia’s main index slipped 0.09%, while Brent crude rose 0.3% to $67.92 a barrel in late trading, pushing individual stock news to the forefront.

But guidance is just that—guidance. If the Pluto shutdown drags on, commissioning hits snags, or Scarborough faces yet another delay, the market’s patience will be stretched thin. It could also shake confidence in the company’s claims of a conservative outlook.

In the next session, desks will focus on broker resets and new positioning in Woodside’s 2026 volume range. They’re also looking for updates on Scarborough hook-up progress and Pluto prep. Oil-linked stocks remain sensitive to overnight crude price swings.

Woodside’s next key date is Feb. 24, when it will release its annual report and hold an investor briefing. This event offers management a crucial opportunity to clarify the cost and timing details that usually influence the stock more than the top-line production figures.

Stock Market Today

  • Asian Shares Fall as Big Tech Slump Hits Global Markets Amid Middle East Tensions
    June 8, 2026, 9:22 AM EDT. Asian shares dropped sharply Monday following Wall Street's worst day since October, driven by a steep decline in the technology sector. South Korea's Kospi plunged 8.3%, led by a 10.2% fall in Samsung Electronics and a 7.7% drop in SK Hynix. Japan's Nikkei 225 declined 3.9%. Wall Street futures showed early gains with Nasdaq up 1.2%. Meanwhile, oil prices surged due to renewed conflict between Israel and Iran, with Brent crude rising to $94.21 a barrel after overnight strikes. The conflict, ongoing since February, continues to disrupt global energy markets and supply chains. European shares showed mixed results, with Germany's DAX down 0.4% and Britain's FTSE 100 up 0.2%. The evolving geopolitical tensions and technology sector weakness underscore global market volatility.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Carvana stock rises after Wells Fargo target hike, but options traders lean defensive
Previous Story

Carvana stock rises after Wells Fargo target hike, but options traders lean defensive

Legal & General share price: LGEN ticks up as L&G names new real assets chiefs, Banner Life sale in focus
Next Story

Legal & General share price: LGEN ticks up as L&G names new real assets chiefs, Banner Life sale in focus

Go toTop